Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors

doi:10.3748/wjg.v30.i11.1533

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3426)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-7) series.

Item

Count

PDF

115

HTML

1882

Figures (1-2)

325

Tables (1-7)

321

Sum=2643

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

118

Download

553

Sum=671

Mar 21, 2024 (publication date) through Mar 10, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 21, 2024; 30(11): 1533-1544
Published online Mar 21, 2024. doi: 10.3748/wjg.v30.i11.1533

Table 1 Comparison of the clinical efficacy of the two treatment regimens [n (%)]

Group	CR	PR	NR	PD	Total effective rate
Research group (n = 50)	7 (14.00)	34 (68.00)	6 (12.00)	3 (6.00)	41 (82.00)
Control group (n = 50)	4 (8.00)	24 (48.00)	17 (34.00)	5 (10.00)	28 (56.00)
χ² value					7.901
P value					0.005

CR: Complete remission; PR: Partial response; NR: No response; PD: Progressed disease.

Citation: Yang LM, Wang HJ, Li SL, Gan GH, Deng WW, Chang YS, Zhang LF. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors. World J Gastroenterol 2024; 30(11): 1533-1544
URL: https://www.wjgnet.com/1007-9327/full/v30/i11/1533.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i11.1533